While TNF-α inhibitors are a mainstay treatment for IBD, there may be therapeutic potential for inflammatory cytokine blockers such as the anti-IL-1β antibody to decrease miRNA mediators and ameliorate cardiac remodeling, but more research will need to be conducted on the mechanisms involved. The gene discussed is TNF; the disease is irritable bowel syndrome.